Repeated anticitrullinated protein antibody and rheumatoid factor assessment is not necessary in early arthritis: Results from the ESPOIR cohort

Journal of Rheumatology

Volumn 41, Issue 1, 2014, Pages 41-46

  Gossec, Laure ^a,b   Paternotte, Simon ^b   Combe, Bernard ^d   Meyer, Olivier ^b,e   Dougados, Maxime ^b,c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Institut Cochin   (France)

^d LAPEYRONIE HOSPITAL   (France)

^e BICHAT HOSPITAL   (France)

Author keywords

Anticyclic citrullinated peptide antibodies; Biomarkers; Laboratory diagnosis; Rheumatoid arthritis; Rheumatoid factor

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; RHEUMATOID FACTOR;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTHRITIS; ARTICLE; COHORT ANALYSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REPEAT PROCEDURE; SEROCONVERSION;

ANTICYCLIC CITRULLINATED PEPTIDE ANTIBODIES; BIOMARKERS; LABORATORY DIAGNOSIS; RHEUMATOID ARTHRITIS; RHEUMATOID FACTOR;

ADULT; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PROSPECTIVE STUDIES; RHEUMATOID FACTOR;

EID: 84891820149     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.121313     Document Type: Article

References (27)

1. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al; T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
2. Gossec L, Combescure C, Rincheval N, Saraux A, Combe B, Dougados M. Relative clinical influence of clinical, laboratory, and radiological investigations in early arthritis on the diagnosis of rheumatoid arthritis. Data from the French Early Arthritis Cohort ESPOIR. J Rheumatol 2010;37:2486-92.
3. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8.
4. Syversen SW, Gaarder PI, Goll GL, Ødegård S, Haavardsholm EA, Mowinckel P, et al. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis 2008;67:212-7.
5. Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-CCP (cyclic citrullinated protein) antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2006;65:845-51.
6. Barra L, Pope J, Bessette L, Haraoui B, Bykerk V. Lack of seroconversion of rheumatoid factor and anti-cyclic citrullinated peptide in patients with early inflammatory arthritis: a systematic literature review. Rheumatology 2011;50:311-6.
7. Mjaavatten MD, van der Heijde DM, Uhlig T, Haugen AJ, Nygaard H, Bjørneboe O, et al. Should anti-citrullinated protein antibody and rheumatoid factor status be reassessed the first year of followup in recent-onset arthritis? A longitudinal study. J Rheumatol 2011;38:2336-41.
8. Combe B, Benessiano J, Berenbaum F, Cantagrel A, Daurès JP, Dougados M, et al. The ESPOIR cohort: a ten-year follow-up of early arthritis in France: methodology and baseline characteristics of the 813 included patients. Joint Bone Spine 2007;74:440-5.
9. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
10. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
11. Visser H, Hazes JM. The diagnosis and prognosis of early arthritis: comment on the editorial by Scott. Arthritis Rheum 2003;48:856-7.
12. Taylor P, Gartemann J, Hsieh J, Creeden J. A systematic review of serum biomarkers anti-cyclic citrullinated peptide and rheumatoid factor as tests for rheumatoid arthritis. Autoimmune Dis 2011;2011:815038.
13. Ursum J, Bos WH, van Dillen N, Dijkmans BA, van Schaardenburg D. Levels of anti-citrullinated protein antibodies and IgM rheumatoid factor are not associated with outcome in early arthritis patients: a cohort study. Arthritis Res Ther 2010;12:R8.
14. Guzian MC, Carrier N, Cossette P, de Brum-Fernandes AJ, Liang P, Ménard HA, et al. Outcomes in recent-onset inflammatory polyarthritis differ according to initial titers, persistence over time, and specificity of the autoantibodies. Arthritis Care Res 2010;62:1624-32.
15. Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 2004;63:1085-9.
16. Rönnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L, et al. Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 2005;64:1744-9.
17. Nell-Duxneuner V, Machold K, Stamm T, Eberl G, Heinzl H, Hoefler E, et al. Autoantibody profiling in patients with very early rheumatoid arthritis: a follow-up study. Ann Rheum Dis 2010;69:169-74.
18. Visser H, leCessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose RA early? Arthritis Rheum 2002;46:357-65.
19. van der Helm-van Mil AH, le Cesie S, van Dongen H, Breedveld FC, Toes RE, Huizinga TW. A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum 2007;56:433-40.
20. Syversen SW, Haavardsholm EA, Bøyesen P, Goll GL, Okkenhaug C, Gaarder PI, et al. Biomarkers in early rheumatoid arthritis: longitudinal associations with inflammation and joint destruction measured by magnetic resonance imaging and conventional radiographs. Ann Rheum Dis 2010;69:845-50.
21. Bas S, Genevay S, Meyer O, Gabay C. Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology 2003;42:677-80.
22. Symmons DP. Classification criteria for rheumatoid arthritis-time to abandon rheumatoid factor? Rheumatology 2007;46:725-6.
23. Meyer O, Nicaise-Roland P, Santos MD, Labarre C, Dougados M, Goupille P, et al. Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritis. Arthritis Res Ther 2006;8:R40.
24. Aman S, Paimela L, Leirisalo-Repo M, Risteli J, Kautiainen H, Helve T, et al. Prediction of disease progression in early rheumatoid arthritis by ICTP, RF, and CRP. A comparative 3-year follow-up study. Rheumatology 2000;39:1009-13.
25. Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 2005;64:196-201.
26. Charni N, Juillet F, Garnero P. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 2005;52:1081-90.
27. Shi J, Knevel R, Suwannalai P, van der Linden MP, Janssen GM, van Veelen PA, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A 2011;108:17372-7.